GlassScriptPhysician profile
Heather A Pryor
NPI 1588697635
$8,853.78
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,405 · 2020: $981 · 2021: $702 · 2022: $2,289 · 2023: $2,138 · 2024: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,457 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,456.80 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,404.90 | 2020-2024 | |
| Novo Nordisk INC | $967.71 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $678.38 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $673.31 | 2019-2024 | |
| Glaxosmithkline, LLC. | $574.87 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $486.62 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $401.01 | 2019-2023 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $368.95 | 2019-2024 | Farxiga |
| Allergan, INC. | $353.71 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $223.23 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.57 | 2019-2024 | Ofev, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.63 | 2019-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $177.69 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $174.29 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $171.23 | 2019-2023 | Trintellix |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Pryor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.